Amylyx Pharmaceuticals’ (Nasdaq: AMLX) shares closed down 3.9% at $13.00 on Monday, despite announcing it has received the first regulatory approval for its Albrioza (sodium phenylbutyrate and ursodoxicoltaurine), from Health Canada, for the treatment of amyotrophic lateral sclerosis (ALS).
Clinical data demonstrated a statistically-significant and clinically-meaningful benefit in functional outcomes for people with ALS taking Albrioza (also known as AMX0035) compared to people taking placebo, either as a stand-alone therapy or when added to existing treatments for ALS.
This decision marks the first marketing approval for Albrioza issued to Amylyx worldwide. A decision on the drug is expected from the US Food and Drug Administration in September.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze